共查询到20条相似文献,搜索用时 15 毫秒
1.
Samko AN Belenkov IuN Batyraliev TA Pershukov IV Niiazova-Karben ZA Sercelik A Calenici O Karaus A Guler N Eryonucu B 《Terapevticheski? arkhiv》2003,75(8):12-17
AIM: Assessment of clinical and angiographic results of a balloon-expandable steel matrix stent TAIS in patients with atherosclerosis of the coronary arteries with no history of previous interventions in the course of an open non-randomized multicenter trial. MATERIAL AND METHODS: The TAIS stent was implanted in 187 patients into 199 stenoses. 47% patients had clinical manifestations of unstable angina pectoris. 29% cases were complicated. The length of the stenoses reached 11.3 +/- 5.4 mm, 22% stenoses were prolonged. RESULTS: This coronary stenting was effective in 100% cases, neither acute nor subacute thromboses were seen. Myocardial infarction without occlusion of the stent developed in 3 patients. The incidence of cardial complications (death, angina, restenosis, repeated revascularization) in 6 month follow-up was 11.8%. An angiographic control in 6 months was made in 184 patients (194 stenoses). The vascular diameter loss index was 0.40 +/- 0.21, a restenosis level--10.7%. A logistic regression analysis has revealed significant correlations between the length of the stent and a target vascular diameter with subsequent restenosis. Repeated revascularization was performed in all the patients with stent restenosis. After control angiography cardiac complications developed in 13.9% patients. Nine month follow-up registered cardiac complications in 17.6% cases. CONCLUSION: The TAIS stent was found effective in prevention of thrombosis and restenosis in patients with a relatively high risk of intervention. 相似文献
2.
Batyraliev TA Samko AN Pershukov IV Niazova-Karben ZA Levitskiĭ IV Ozgul S Serchelik A Pia Iu Besnili F Dinler G Aialp MR 《Terapevticheski? arkhiv》2002,74(2):57-60
AIM: To assess immediate and long-term outcomes after BioDiamond-stent implantation in patients with native coronary artery disease. MATERIALS AND METHODS: The BioDiamond stent was implanted in 112 patients with 132 de novo lesions. Most patients (54%) had unstable angina, 33% of the lesions were of type B2-C. RESULTS: No stent deployment failure occurred as well as acute or subacute stent thrombosis. The 6-month angiographic follow-up was obtained in 108 patients (98%) (125 lesions). The loss index was 0.40 +/- 0.27. Angiographic restenosis rate occurred in 14%. Repeat target lesion revascularization was successful in 16 patients with restenosis. CONCLUSION: The results of this study indicate a potential benefit of BioDiamond for prevention of stent thrombosis and restenosis in these relatively high-risk patients. 相似文献
3.
Samko AN Pershukov IV Batyraliev TA Niiazova-Karben ZA Kalenich O Karaus A Giuler N Erenuchu B Kadayĭfchi S Temamogullari A Ozgul' S Akgul' F Levitskiĭ IV Sozytkin AV Besnili F Arful' F Zhamgyrchiev ShT Serchelik A Shengul Kh Daniiarov BS Demirbash O Belenkov IuN 《Terapevticheski? arkhiv》2003,75(4):47-51
AIM: An open non-randomized trial was initiated to assess clinical and angiographic results of using the coronary stent "Ephesos" in 457 patients with stable or unstable angina pectoris and native coronary affections. MATERIAL AND METHODS: 268 stents have been implanted in 231 patients with stable angina (SA) and 271 stents--in 226 patients with unstable angina (UA). 46% lesions were complicated. The length of stenosis was 12.9 +/- 6.7 mm in the group SA and 14.1 +/- 7.4 mm in the group UA, 30% stenoses were long. RESULTS: Successful stenting was stated in 99% without cases of acute thrombosis. Non-fatal myocardial infarction took place in hospital in 1.3% of SA patients and in 2.6% of UA patients. Incidence of cardiac complications (death, recurrent angina pectoris, myocardial infarction, restenosis, repeated revascularization) for 6-month follow-up was 15.6% in SA group and 18.1% in UA group. At angiographic control, the index of vascular diameter loss made up 0.22 +/- 0.2 in SA group and 0.3 +/- 0.27 in UA group. Incidence of restenosis was 12 and 14%, respectively. 18-month follow-up found no differences in frequency of complications: 21.6 and 22.6% in groups SA and UA, respectively. CONCLUSION: Implantation of the stent "Ephesos" is effective in prevention of thrombosis and restenosis in patients with stable or unstable angina pectoris at high risk of intervention. 相似文献
4.
背景:紫杉醇药物洗脱支架临床应用的安全性和有效性已经国际临床试验研究证实,在适当放宽病变的入选标准情况下,其再狭窄发生率仍明显低于金属裸支架.目的:通过对应用紫杉醇药物洗脱支架的患者进行冠状动脉造影随访,观察该支架再狭窄发生情况和支架对局部血管的作用,探讨支架材料与宿主的生物相容性.设计:随访观察.单位:解放军总医院心内科.对象:选择2003-05/2005-05解放军总医院心血管内科有冠状动脉介入治疗指征,且行紫杉醇药物洗脱支架置入的冠心病患者297例,男265例,女32例,年龄36~76岁.患者均对治疗和实验知情同意;该实验经医院伦理委员会批准.方法:全部患者置入美国Boston Scientific生产的紫杉醇药物洗脱支架.患者支架术后6和12个月回院复查,并于术后6个月行冠状动脉造影,测量数据包括:靶血管参考管径、最小管腔直径,计算直径狭窄率、晚期管腔丢失情况.主要观察指标:紫杉醇药物洗脱支架置入后6个月冠状动脉造影结果,随访支架材料与宿主的生物相容性.结果:①冠状动脉造影定量分析结果:冠状动脉造影随访时,晚期管腔支架内丢失显著高于支架近端边缘及支架远端边缘,差异有显著性意义(P<0.05).②支架再狭窄的随访:6个月时冠动脉造影有14例发生再狭窄,再狭窄发生率为10.4%(14/134).再狭窄的类型以支架内弥漫性再狭窄7例.再血管化率为6.7%.③支架动脉瘤形成:冠状动脉造影随访时显示支架部位有小动脉瘤形成1例,动脉瘤发生率为0.75%(1/134).④心血管不良事件:支架置入后1例4个月发生猝死,猝死发生率为0.34%(1/297).支架置入后5d发生支架内亚急性血栓形成1例,发生率0.34%(1/297).术后12个月晚期血栓形成2例,总心血管不良事件发生率为1.35%.结论:①紫杉醇药物洗脱支架的管腔丢失主要在支架内,置入后再狭窄以支架内弥漫性多见,心血管不良事件发生率较低.②紫杉醇药物洗脱支架可导致靶病变血管局部小的瘤样扩张.术后及随访结果总体数据显示紫杉醇药物洗脱支架与患者的生物相容性较好. 相似文献
5.
国产Firebird支架与Cypher支架在急性心肌梗死患者中的临床对比研究 总被引:2,自引:0,他引:2
目的 通过对比研究的方法评价国产Firebird雷帕霉素涂层支架与进口Cypher雷帕霉素涂层支架在急性心肌梗死患者中应用的安全性和有效性.方法 选择我院2004年12月至2006年2月诊断为急性ST段抬高型心肌梗死且发病12小时以内患者中接受Firebird支架的患者38例(Firebird组),接受Cypher支架治疗的患者43例(Cypher组).观察两组住院期间和6个月随访期间的心血管事件及支架内再狭窄的发生情况.结果 住院期间Firebird组无急性、亚急性血栓形成及心绞痛事件发生,9例术后6个月复查冠状动脉造影(3例有心绞痛事件)均未见支架内再狭窄;Cypher组2例于术后复发胸痛,原ST段抬高导联再次抬高,急诊冠状动脉造影示亚急性血栓形成,再次开通.8例术后6个月复查冠状动脉造影(4例有心绞痛事件)1例显示支架内再狭窄,再次植入药物支架.两组各有3例患者心绞痛事件与非支架血管有关.结论 国产Firebird支架在急性心肌梗死患者中应用具有同Cypher支架一致的安全性和有效性. 相似文献
6.
Jörg Carlsson MD FESC Burhard von Wagenheim Rikard Linder Tahir M. Anwari Jeanette Qvist Iren Petersson Theo Magounakis Bo Lagerqvist 《Clinical research in cardiology》2007,96(2):86-93
Summary
Background
Randomized studies have not found an increased rate of late stent thrombosis (LAST) in drug-eluting stents (DES) compared
with bare metal stents (BMS) but those studies were statistically not powered to show such a difference. At the same time
there is an increasing number of reports of LAST in DES patients in the current literature.
Patients and methods
We tried to describe the incidence of LAST in an unselected DES and BMS patient population. All patients who underwent stenting
in our hospital between October 2003 and March 2006 were included in the study (n=1377). A total of 424 (30.1%) patients were
treated with only BMS stents, 520 (37.8%) with paclitaxel-eluting stents (PES), 384 (27.9%) with sirolimus-eluting stents
(SES) and 49 (3.6%) with BMS and DES. Long-term follow-up of all patients was used to determine the incidence of LAST as defined
by angiographically proven stent thrombosis associated with acute symptoms more than 30 days after stent implantation. Followup
was between 1 month and 2 years 7 months (mean 12 months). Patients treated with DES were younger (66±11 years) than BMS patients
(72±10 years; p<0.001) and more often had diabetes (24.2% vs 17.4%; p < 0.001). A previous PCI had been performed in 27.1%
of DES patients vs 13.9% of BMS patients (p < 0.001).
Results
There were 9 cases of LAST: 2 with SES (at 6 and 11 months after implantation), 6 with PES (at 6, 9 (2×), 10, 16 and 26 months),
and one with BMS (at 22 months). All patients with LAST presented with STEMI and without an angina history that suggested
restenosis. Two cases were related to complete cessation of antiplatelet therapy, one because of patient non-compliance (SES),
one after aspirin was stopped for orthopedic surgery (BMS). Two cases occurred within 1 month of cessation of clopidogrel
therapy and while these patients were on aspirin therapy. Five cases occurred on aspirin monotherapy 2, 3, 4, 10 and 20 months,
respectively after planned cessation of clopidogrel. None of the cases occurred under dual antiplatelet therapy. All patients
underwent primary PCI; none died.
Conclusion
Angiografically proven LAST occurred in our unselected patient population with an incidence of 0.84% in patients treated with
DES and 0.21% in BMS patients within a mean follow-up of 12 months (p = 0.36). LAST may indeed occur in clinically stable
patients while on aspirin monotherapy. Since LAST led in all patients to STEMI it seems to be a serious clinical issue that
prompts further investigation and discussion of length of dual platelet therapy. 相似文献
7.
目的:分析冠状动脉内药物支架(drug-eluting stent,DES)支架内血栓(stent thrombosis)及裸金属支架(bare metalstent,BMS)内血栓形成的原因。方法:回顾分析1502例术后发生支架内血栓的支架植入患者的临床资料,观察其性别、年龄、病变血管、支架长度和服药情况,分析支架内血栓形成原因。结果:植入药物洗脱支架后9例患者发生支架内血栓,年龄为(70.3±8.3)岁。9例发生支架内血栓患者中,有7例经冠状动脉造影证实,急性血栓1例,亚急性血栓2例,晚期血栓2例,极晚期4例。临床表现为急性心肌梗死7例,其中2例为不稳定心绞痛,死亡2例。其中3例停用氯吡格雷,1例因上消化道出血停用阿司匹林。植入裸金属支架后发生支架内血栓11例,患者平均年龄为(78.2±6.6)岁,其中3例经冠状动脉造影证实,发生率为1.51%,其中表现为急性心梗为5例,6例表现为不稳定心绞痛,死亡5例。结论:冠脉支架内血栓大多与抗血小板治疗不充分有关,但由于患者数较少,对支架植入术后支架内血栓问题还应进行更深入的研究。 相似文献
8.
目的 探讨单支血管病变的冠心病患者经皮冠状动脉介入术中植入NeoVas生物可吸收支架的远期疗效及安全性.方法 单支血管病变的冠心病患者28例,均行经皮冠状动脉介入术,术中植入NeoVas生物可吸收支架,随访观察远期预后及不良反应发生情况.结果 28例患者单支血管病变长度(17.68±2.51)mm,管腔狭窄程度75%~... 相似文献
9.
目的 探讨冠状动脉药物洗脱支架内再狭窄的危险因素.方法 对157例行冠状动脉药物洗脱支架植入术患者的临床资料进行回顾性分析,按照冠状动脉造影结果分为再狭窄组33例和无再狭窄组124例,采用单因素及Logistic多因素回归分析其临床及冠状动脉造影特征与药物洗脱支架内再狭窄的相关性.结果 再狭窄组33例,糖尿病18例(54.5%),术后反复心绞痛26例(78.8%);无再狭窄组124例,糖尿病31例(25.0%),术后反复心绞痛72例(58.1%),组间差异有统计学意义(χ2=10.60,P<0.01;χ2=4.77,P=0.03).2组慢性完全闭塞分别为11例(19.3%)、12例(7.6%),分叉病变12例(21.1%)、16例(10.2%),弥漫病变15例(26.3%)、19例(12.1%),组间差异有统计学意义(χ2值分别为5.92、4.34、6.32,P均<0.05).再狭窄组植入支架57枚,无再狭窄组植入157枚.Logistic多因素分析显示糖尿病、术后反复心绞痛、慢性完全闭塞、分叉病变、弥漫病变和支架长度与支架内再狭窄相关(OR分别为3.52、2.59、3.05、3.14、3.08、0.93,95%CI分别为1.56~7.90,1.02~6.59,1.11~8.36,1.30~7.59,1.34~7.05,0.88~0.98,P均<0.05).结论 冠状动脉药物洗脱支架植入术后,糖尿病史、术后反复发生心绞痛、慢性完全闭塞、分叉病变、弥漫病变及支架长度为支架内再狭窄的危险因素.Abstract: Objective To investigate the risk factors of in-stent restenosis (ISR) after coronary implantation of drug-eluting stent Methods One hundred and fifty-seven patients including 118 males and 39 females,who underwent successful implantation of drug-eluting stent, were recruited in the study. The patients were divided into the restenosis group (33 patients) and non-restenosis group ( 124 patients) according to the angiographic results. The associations of ISR with clinical and coronary angiographic characteristics were analyzed using univiriate analysis and logistic regression. Results In the restenosis group,there were 18 cases of diabetes mellitus ( 54. 5% ), 26 cases of frequency angina ( 78. 8% ), which were significantly higher than those of 31 cases of diabetes (25.0%) and 72 case of frequent angina (58. 1% ) in the non-restenosis group (χ2 = 10. 60, P < 0. 01, χ2 = 4. 77, P = 0. 03 for diabetes mellitus and frequent angina, respectively). Compared to non-restenosis group, the occurrence rates of chronic total occasion, bifurcatus lesions, diffuse lesions were significandy higher in the restenosis group ( 19. 3% vs 7. 6% χ2 =5.92,21.1% vs 10. 2% χ2 =4. 34,26. 3%vs 12. 1% χ2 =6. 32,Ps <0. 05). Fifty-seven stents were implanted into the restenosis group,and one hundred and fifty-seven into the non-restenosis group. Logistic regression analysis showed that diabetes, frequent angina,chronic total occlusion lesions, bifurcatus lesions, diffuse lesions, stent length and diameter were significantly associated with restenosis ( OR value were 3.52,2. 59,3.05,3. 14,3.08,0. 93,95% CI were 1.56 - 7.90,1.02 - 6. 59,1.11 - 8. 36,1.30 - 7.59,1.34 - 7.05,0. 88 - 0. 98 respectively, Ps < 0. 05 ). Conclusion After implantation of drug-eluting stent, diabetes mellitus, chronic total occasion lesions, frequent angina, diffuse lesions, bifurcatus lesions and stent length and diameter are associated with follow-up restenosis. 相似文献
10.
Karaca I Aydin K Yavuzkir M Ilkay E Akbulut M Isik A Arslan N 《The Journal of international medical research》2005,33(4):389-396
In-stent restenosis is a major problem following coronary stent implantation, and inflammation plays an active role. We evaluated the effectiveness of the inflammatory marker C-reactive protein (CRP) as a predictor of in-stent restenosis after successful stent implantation, in 86 patients with unstable angina pectoris. Plasma CRP was measured in all patients before the procedure, and at 48 - 72 h and 1, 2 and 3 months post-procedure. An angiographic loss of 50% at follow-up was accepted as in-stent restenosis. We found negative and positive predictive values of the pre-procedural plasma CRP for determining 6-month in-stent restenosis of 34% and 61%, respectively. We also found a strong correlation between the 3-month post-procedural CRP value and 6-month in-stent restenosis; the negative and positive predictive values being 8% and 76%, respectively. In conclusion, we showed that a plasma CRP value > 3 mg/l in the third month after coronary stent implantation was a strong predictor of angiographic in-stent restenosis. 相似文献
11.
目的评价紫杉醇洗脱冠状动脉支架(TAXUStmBoston公司产品)应用于急性冠状动脉综合症病人的临床疗效及安全性。方法自2003年5月至2004年12月接受TAXUS支架治疗的94例急性冠状动脉综合症患者,观察术后即刻效果、术后6个月心脏性死亡、心肌梗塞、再次血管重建及冠状动脉造影复查情况。病例中包括ST段抬高的急性心肌梗塞27例,非ST段抬高的急性心肌梗死8例,不稳定心绞痛59例。结果支架植入成功率为99%,术中和随访期间无死亡,术后1例出现亚急性血栓,1例晚期血栓致心肌梗塞,另有5例随访中进行了血管重建术,6个月主要心脏不良事件(MACE)发生率7.4%。术后6~7个月23例的冠状动脉造影复查再狭窄率为13.0%(支架内为8.6%),靶病变重建率为2.7%。结论应用TAXUS支架治疗急性冠状动脉综合症是安全和有效的,支架内再狭窄率明显低于普通金属支架。 相似文献
12.
目的探讨肝移植(LT)术后肝动脉并发症血管内介入治疗的安全性和有效性。方法回顾性分析2010年1月~2015年2月我院12例肝移植术后经影像学证实的肝动脉并发症的临床资料。包括肝动脉血栓形成(HAT)5例,肝动脉狭窄(HAS)3例,HAS合并HAT 2例,肝动脉假性动脉瘤(HAP)合并HAS 2例,对肝动脉血栓形成、肝动脉狭窄程度超过50%及肝动脉假性动脉瘤形成者行介入治疗。结果成功治疗10例,技术包括导管内溶栓(CDT),经皮腔内血管成形术(PTA)及支架植入术(stent placement),技术成功率83%(10/12)。1例在PTA过程中破裂,成功植入覆膜支架,1例在溶栓过程中出现少量出血,经保守治疗后好转。术后两周血清丙氨酸氨基转氨酶(ALT)、天门冬氨酸氨基转氨酶(AST)、总胆红素(TBil)及直接胆红素(DBil)明显降低(P0.01)。随访2~24个月,2例因术后再狭窄和急性血栓形成再次介入治疗,余患者未出现介入相关并发症。结论血管内介入治疗可作为肝移植术后肝动脉并发症的一线治疗方法。 相似文献
13.
国产可降解雷帕霉素药物洗脱支架置入的疗效评价:与金属裸支架比较 总被引:2,自引:1,他引:1
背景:药物洗脱支架明显降低了再狭窄率,但永久聚合物涂层在抑制血管平滑肌细胞增生的同时,阻碍血管完全内皮化进程,促使再狭窄发生,且永久聚合物涂层可引发晚期血栓等并发症。目的:观察冠心病合并糖尿患者置入国产可降解药物洗脱支架后的远期疗效和安全性,并与置入金属裸支架患者进行比较。方法:实验组选择冠心病合并2型糖尿病患者136例,首次经皮冠状动脉成形治疗,置入国产可降解药物洗脱支架(EXCELTM),并以同期行金属裸支架置入治疗的冠心病合并2型糖尿病患者87例为对照组,随访12个月以上,记录主要不良心血管事件发生情况,并复查冠状动脉造影。结果与结论:实验组129例,对照组83例完成(13.5±3.5)个月随访,实验组及对照组分别有8例及12例患者发生不良心血管事件,两组间差异有显著性意义(P=0.045),对照组靶血管血运重建及再发心绞痛多于实验组(P<0.05)。两组患者随访冠状动脉造影的定量分析提示实验组最终丢失指数小于对照组(P<0.05),再狭窄率低于对照组(P<0.05)。说明对于冠心病合并糖尿病患者,应用国产可降解药物洗脱支架可降低不良心血管事件发生率,减少再狭窄,改善患者远期预后,安全性能良好。 相似文献
14.
Norgaz T Hobikoglu G Serdar ZA Aksu H Alper AT Ozer O Narin A 《The Tohoku journal of experimental medicine》2005,206(3):243-246
Although many patients with coronary artery disease are being treated by coronary stents, in-stent restenosis is the major limitation of percutaneous coronary stenting procedures. Most stents are made of stainless steel, and that, allergic reactions to nickel ions released from coronary stainless-steel stents may be one of the triggering mechanisms for in-stent restenosis. We aimed to evaluate the relationship between in-stent restenosis and nickel allergy in a prospective study. For this purpose, we applied epicutaneous patch test for nickel in 43 patients who had undergone elective intracoronary stent placement for stable angina pectoris in the day following stent placement and evaluated the presence of nickel allergy. Control angiography was performed at 6 months to determine in-stent restenosis. Three (6.9%) patients had allergic reaction to nickel and 16 (37%) patients had developed in-stent restenosis. One of the 3 patients with nickel allergy had diffuse in-stent restenosis and the others not. The present study therefore does not support the proposed relationship between nickel allergy and development of in-stent restenosis in patients having stainless steel stents. Large scale studies are needed to reach a final conclusion. 相似文献
15.
目的 评价彩色多普勒超声在锁骨下动脉狭窄诊断及血管内支架植入术后随访中的价值.方法 对38例动脉粥样硬化性脑梗死或一过性脑缺血患者行数字减影血管造影(DSA)和彩色多普勒超声检查,检出锁骨下动脉近心段中至重度狭窄或闭塞44支(6例双侧),40支行血管内成形和支架植入术,术后彩色多普勒超声对锁骨下动脉支架情况进行随访.结果 锁骨下动脉动脉粥样硬化性阻塞主要局限于近心段.彩色多普勒超声诊断锁骨下动脉近心段阻塞与DSA的符合率达90.9%(40/44).35支锁骨下近心段阻塞合并盗血.手术成功率95%(38/40).术后平均随访18个月(3~63个月),发现8支支架植入术后再狭窄,分别为支架内内膜增生狭窄6支,支架弹性回缩及支架断裂塌陷狭窄各1支,血管植入支架后再狭窄率21.1%(8/38).无严重并发症发生.结论 彩色多普勒超声诊断锁骨下动脉近心段狭窄准确可靠,可作为锁骨下动脉近心段阻塞性病变介入术前评价和术后随访中的首选手段. 相似文献
16.
目的:评价药物洗脱支架治疗支架内再狭窄的长期疗效。方法:经药物洗脱支架治疗的支架内狭窄患者63例,平均随访22个月,观察有无主要心脏不良事件发生。结果:63例患者中,主要心脏不良事件的发生率为46.5%,未发生支架内血栓形成及心肌梗死事件。药物洗脱支架治疗药物洗脱支架术后支架内再狭窄疗效优于金属裸支架术后支架内再狭窄。Logistic多因素分析显示,药物洗脱支架治疗支架内再狭窄的疗效与年龄、性别、病变严重程度、病变直径、原支架种类及药物支架涂层材料无显著相关。结论:药物洗脱支架治疗支架内再狭窄安全、有效。 相似文献
17.
Treatment of vertebral artery origin stenosis with a Pharos stent device: a single center experience
Broussalis E Kunz AB Luthringshausen G Klein S McCoy MR Trinka E Killer-Oberpfalzer M 《Interventional neuroradiology》2011,17(3):316-322
Atherosclerotic stenosis of vertebral artery (VA) origin exceeding 70% severity accounts for one third of all vertebrobasilar strokes. For a period of one year the results of endovascular treatment of VA stenosis with the new Pharos stent device were assessed.Twenty-two patients with symptomatic VA stenosis were treated with the Pharos stent. Clinical status and stenosis grade were documented before treatment and 24 hours, one, three and twelve months after treatment via ultrasound and magnetic resonance tomography.All procedures proved to be technically successful without the occurrence of intra-procedural complications. During the observation period of more than one year, 55% of patients were documented with a mean stenosis degree of 60%: two (10%) of these patients showed a residual stenosis after angioplasty and nine patients (45%) an in-stent restenosis, whereas only two patients were documented with a hemodynamically relevant in-stent restenosis of 80%. These two patients were retreated with balloon dilatation. None of the patients showed neurological deterioration or new abnormalities at magnetic resonance tomography examination. Neither VA occlusion nor restenosis of the contralateral VA negatively affected the clinical outcome. An in-stent restenosis was developed by more female than male patients.VA origin stenting with the Pharos stent device is an effective treatment of stenosis. The good clinical results compared to the high restenosis rates have to be examined in further studies. Pin particular, it has to be determined whether the Pharos stent allows the vessel time for collateralization, whether double antiplatelet treatment prevents recurrent cerebrovascular events or whether merely the low restenosis degree is causative for the clinical outcome. 相似文献
18.
选择2002-01/12进行冠状动脉内支架置入成功128例冠心病心绞痛患者为观察对象.①随访6-18个月,以冠状动脉造影检查直径狭窄率≥50%为支架内再狭窄,128处病变再狭窄36处,再狭窄率28.1%.再狭窄组血脂蛋白(a)水平明显高于无再狭窄组(P<0.01).②按照患者血脂蛋白(a)的水平,把患者分为高脂蛋白(a)组[脂蛋白(a)浓度≥230 mg/L]和低脂蛋白(a)组[脂蛋白(a)浓度<230 mg/L].高脂蛋白(a)组再狭窄率高于低脂蛋白(a)组(P<0.05).血管内超声观察高脂蛋白(a)组冠状动脉支架置入后新生内膜面积、新生内膜体积高于低脂蛋白(a)组(P<0.01).⑨相关分析表明脂蛋白(a)与新生斑块面积及体积呈正相关(P<0.05). 相似文献
19.
G Christ M Nikfardjam R Huber-Beckmann M Gottsauner-Wolf D Glogar B R Binder J Wojta K Huber 《Journal of thrombosis and haemostasis》2005,3(2):233-239
BACKGROUND: The plasmin activation system is involved in the development of restenosis after percutaneous coronary interventions (PCI). Conflicting data exist concerning the role of plasminogen activator inhibitor-1 (PAI-1) and its predictive value for restenosis. OBJECTIVES: To evaluate the fibrinolytic response to injury after PCI with or without stent implantation on different antithrombotic medications and its relation to late restenosis. PATIENTS AND METHODS: Eighty consecutive patients with successful PCI without (balloon only; n = 37) or with stent implantation (stent; n = 43) on different antithrombotic regimes (balloon only, aspirin; stent, aspirin/coumadin/dipyridamole vs. aspirin/ticlopidine). Blood samples were taken at baseline and up to 7 days after PCI and PAI-1 active antigen and tissue plasminogen activator (t-PA) antigen were determined. Restenosis was angiographically determined after 6 months. RESULTS: PCI increased both t-PA and PAI-1 levels (P < 0.001), with a significant prolonged and pronounced increase in stent vs. balloon-only patients (P < 0.05). Restenosis (stent 26%; balloon 38%) was significantly correlated to an attenuated PAI-1 increase after 24 h in the ticlopidine group (P = 0.007; restenosis, relative Delta PAI-1 + 50 +/- 28%; non-restenosis, + 139 +/- 50%), but not in the coumadin group. In the balloon-only group late restenosis (ISR) was associated with a trend for an augmented PAI-1 increase after 24 h. CONCLUSIONS: Coronary stent implantation significantly increases t-PA and PAI-1 plasma levels up to 1 week compared with balloon angioplasty alone. ISR in ticlopidine-treated patients was associated with an attenuated early PAI-1 active antigen increase. A less than 50% increase 24 h after stent implantation under ticlopidine treatment may identify patients at risk for the development of ISR. 相似文献
20.
症状性颅内动脉狭窄血管内支架成形术围手术期脑血管并发症的临床分析 总被引:1,自引:0,他引:1
目的:观察症状性颅内动脉狭窄血管内支架成形术的围手术期脑血管并发症,并探讨其相关危险因素。方法:回顾性分析169例接受血管内支架成形术的症状性颅内动脉狭窄患者(181处病变,狭窄率≥50%)脑血管并发症的发病情况。结果:20例(11.8%)出现脑血管并发症:脑卒中10例(5.9%),其中症状性脑出血4例,死亡2例;缺血性卒中6例;靶病变部位急性血栓形成6例,经动脉内溶栓后即刻再通,均无后遗症;无症状性脑出血2例;短暂性脑缺血发作1例;无症状性动脉夹层1例。围手术期未规范抗血小板治疗与靶病变部位急性血栓形成显著相关(P=0.027);分层分析结果显示同一个部位双支架串联植入与并发颅内出血显著相关(P=0.005)。结论:症状性颅内动脉狭窄血管内支架成形术的脑血管并发症表现形式多样,同一个部位双支架串联植入是并发脑出血的一个独立危险因素,围手术期未规范抗血小板治疗易导致靶病变部位急性血栓形成。 相似文献